Do sluggish cognitive tempo symptoms predict response to methylphenidate in patients with attention-deficit/hyperactivity disorder-inattentive type?

J Child Adolesc Psychopharmacol

ADHD Outpatient Program, Division of Child Psychiatry, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil .

Published: August 2009

In this naturalistic study, we assessed the effect of sluggish cognitive tempo (SCT) symptoms in the response to methylphenidate (MPH) in 88 children and adolescents with attention-deficit/hyperactivity disorder-Inattentive Type (ADHD-I) according to Diagnostic and Statistical Manual of Mental Disorders, 4(th) edition (DSM-IV) criteria. SCT symptoms were assessed in these subjects by means of the Child Behavior Checklist (CBCL) scale. The response to MPH after 1 month of treatment was assessed by parental scores in the Swanson, Nolan, and Pelham Questionnaire-Version IV (SNAP-IV) scale. No significant differences were found between subjects with and without SCT symptoms in the response to MPH either assessing presence of SCT symptoms categorically (at least 1 symptom) or dimensionally (p < 0.5 for both analyses; effect size [ES] = 0.24). Our findings corroborate previous phenotypic data suggesting that SCT symptoms do not define a clinically relevant type of ADHD-I.

Download full-text PDF

Source
http://dx.doi.org/10.1089/cap.2008.0115DOI Listing

Publication Analysis

Top Keywords

sct symptoms
20
sluggish cognitive
8
cognitive tempo
8
response methylphenidate
8
attention-deficit/hyperactivity disorder-inattentive
8
symptoms response
8
type adhd-i
8
response mph
8
symptoms
6
sct
5

Similar Publications

Acute lymphoblastic leukemia (ALL) is a malignant condition of lymphoid progenitor cells that primarily affects the pediatric population, but also adults. The 5-year survival rate is 90% in children and approximately 40% in adults, with survival increasing through the use of peripheral stem cell allotransplantation (SCT). The relapse rate after stem cell transplantation (SCT) in adult acute lymphoblastic leukemia (ALL) patients ranges from 35% to 45%, making relapse a major cause of death in this population.

View Article and Find Full Text PDF

Background/objectives: (ALS), or Lou Gehrig's disease, is a debilitating, incurable neurodegenerative disorder characterised by motor neuron death in the spinal cord, brainstem, and motor cortex. With an incidence rate of about 4.42 cases per 100,000 people annually, ALS severely impacts motor function and quality of life, causing progressive muscle atrophy, spasticity, paralysis, and eventually death.

View Article and Find Full Text PDF

Purpose: Conventional radiotherapy (CRT) has limited local control and poses a high risk of severe toxicity in large lung tumors. This study aimed to develop an integrated treatment plan that combines CRT with lattice boost radiotherapy (LRT) and monitors its dosimetric characteristics.

Methods: This study employed cone-beam computed tomography from 115 lung cancer patients to develop a U-Net +  + deep learning model for generating synthetic CT (sCT).

View Article and Find Full Text PDF

Objective: Self-report measures of ARFID symptoms (e.g., Nine-Item Avoidant/Restrictive Food Intake Disorder Screen [NIAS]) are used to assess symptom differences between groups.

View Article and Find Full Text PDF

This paper explores a novel challenge regarding bidirectional Automated Guided Vehicles (AGVs): supervisory control amidst potential sensor faults. The proposed approach uses an event-based control architecture, guided by Supervisory Control Theory (SCT), to achieve non-blocking routing of AGVs. Unlike most routing approaches assuming full event observability, this paper investigates scenarios where events might become unobservable due to sensor faults or disturbances, which may affect the supervisor efficiency.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!